GYRE
vs
S&P 500
GYRE
S&P 500
Over the past 12 months, GYRE has underperformed S&P 500, delivering a return of -23% compared to the S&P 500's +12% growth.
Stocks Performance
GYRE vs S&P 500
Performance Gap
GYRE vs S&P 500
Performance By Year
GYRE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Gyre Therapeutics Inc
Glance View
Gyre Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2006-04-12. Gyre Therapeutics, Inc., formerly Catalyst Biosciences, Inc., is a biotechnology company. The firm is focused on organ fibrosis and inflammatory diseases. The firm is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The firm is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase 3 trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase 1 trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.
